PET with small molecules targeting prostate-specific membrane antigen (PSMA) is being
adopted as a clinical standard for prostate cancer imaging. In this study, we evaluated …

Measurements of metabolically active tumor volume (MATV) can be applied to 18F-
fluorocholine PET/CT to quantify whole-body tumor burden. This study evaluated the serial …

Our objective was to investigate the lesion detection rate of 18F-DCFPyL PET/CT, a prostate-
specific membrane antigen (PSMA)–targeted PET agent, in patients with biochemically …

Aim: High rate of non-target lesions in metastatic castration-resistant prostate cancer usually
limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and …

Objective: We investigated the role of 18F-fluorocholine positron emission
tomography/computed tomography (FCH-PET/CT) in the early evaluation of abiraterone and …

Background We aimed to test whether the prognostic value of 18 F‐Fluorodeoxyglucose
Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic …

For patients with metastatic castration-resistant prostate cancer (mCRPC), no reliable
biomarkers for predicting therapeutic response or assisting in treatment selection and …

Background Prostate-specific membrane antigen (PSMA)-based positron emission
tomography (PET) imaging is a highly sensitive tool for the detection of prostate cancer …

18F-DCFPyL is a small-molecule inhibitor of the prostate-specific membrane antigen that
has shown promise for evaluation of primary and metastatic prostate cancer using PET …

Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has shown
encouraging results for treatment of metastatic castration-resistant prostate cancer (mCRPC) …